Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem-specific human B cells.
Mantus GE, Chopde AJ, Gorman J, Cominsky LY, Ourahmane A, Creanga A, Shimberg GD, Gillespie RA, Van Wazer DJ, Zhou T, Gajjala SR, Williams C, Maestle E, Reed DS, Serebryannyy L, Costner P, Holman L, Casazza JP, Koup RA, Dropulic LK, Kwong PD, McDermott AB, Kanekiyo M, Andrews SF. Mantus GE, et al. Among authors: holman l. Sci Transl Med. 2025 Jan;17(779):eadr8373. doi: 10.1126/scitranslmed.adr8373. Epub 2025 Jan 1. Sci Transl Med. 2025. PMID: 39742506
Tracing early pastoralism in Central Europe using sedimentary ancient DNA.
Zampirolo G, Holman LE, Sawafuji R, Ptáková M, Kovačiková L, Šída P, Pokorný P, Pedersen MW, Walls M. Zampirolo G, et al. Among authors: holman le. Curr Biol. 2024 Oct 21;34(20):4650-4661.e4. doi: 10.1016/j.cub.2024.08.047. Epub 2024 Sep 20. Curr Biol. 2024. PMID: 39305897
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.
Casazza JP, Hofstetter AR, Costner PJM, Holman LA, Hendel CS, Widge AT, Wu RL, Whalen WR, Cunningham J, Arthur A, Wang X, Ola A, Saunders J, Mendoza F, Novik L, Burgos Florez MC, Ortega-Villa AM, Apte PJ, Strom L, Wang L, Imam M, Basappa M, Naisan M, Castro M, Trost JF, Narpala SR, Vanderven HA, Yamshchikov GV, Berkowitz NM, Gordon IJ, Plummer SH, Wycuff DL, Vazquez S, Gillespie RA, Creanga A, Adams WC, Carlton K, Gall JG, McDermott AB, Serebryannyy LA, Houser KV, Koup RA, Graham BS, Ledgerwood JE, Mascola JR, Pierson TC, Andrews SF, Kanekiyo M, Dropulic LK; VRC 323 study team. Casazza JP, et al. Among authors: holman la. NPJ Vaccines. 2024 Sep 17;9(1):171. doi: 10.1038/s41541-024-00959-0. NPJ Vaccines. 2024. PMID: 39289377 Free PMC article.
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A. Monk BJ, et al. Among authors: holman ll. Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14. Ann Oncol. 2024. PMID: 39284381 Free article. Clinical Trial.
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Brown J, et al. Among authors: holman ll. Gynecol Oncol. 2024 Nov;190:283-290. doi: 10.1016/j.ygyno.2024.09.002. Epub 2024 Sep 12. Gynecol Oncol. 2024. PMID: 39265466 Clinical Trial.
From whole bodies to single cells: A guide to transcriptomic approaches for ecology and evolutionary biology.
Hoedjes KM, Grath S, Posnien N, Ritchie MG, Schlötterer C, Abbott JK, Almudi I, Coronado-Zamora M, Durmaz Mitchell E, Flatt T, Fricke C, Glaser-Schmitt A, González J, Holman L, Kankare M, Lenhart B, Orengo DJ, Snook RR, Yılmaz VM, Yusuf L. Hoedjes KM, et al. Among authors: holman l. Mol Ecol. 2024 Jun 10:e17382. doi: 10.1111/mec.17382. Online ahead of print. Mol Ecol. 2024. PMID: 38856653
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Pitiyarachchi O, Ansell PJ, Coleman RL, Dinh MH, Holman L, Leath CA 3rd, Werner T, DiSilvestro P, Morgan M, Tew W, Lee C, Cunningham M, Newton M, Edraki B, Lim P, Barlin J, Spirtos NM, Tewari KS, Edelson M, Reid T, Carlson J, Friedlander M. Pitiyarachchi O, et al. Among authors: holman l. Gynecol Oncol. 2024 Aug;187:221-226. doi: 10.1016/j.ygyno.2024.05.021. Epub 2024 May 30. Gynecol Oncol. 2024. PMID: 38821039 Free article. Clinical Trial.
200 results